PULMONARY AND SYSTEMIC KILLING OF OPPORTUNISTIC FUNGI
Project Number5R01AI015338-16
Contact PI/Project LeaderDIAMOND, RICHARD D
Awardee OrganizationBOSTON MEDICAL CENTER
Description
Abstract Text
DESCRIPTION: (Adapted from applicant's abstract) Opportunistic mycoses
continue to increase in frequency and importance. In 3 of the most common
of these, candidiasis, aspergillosis, and mucormycosis, hyphae must be
cleared from lesions, primarily by neutrophils (PMN), to prevent
progressive disseminated infections. These studies focus upon a stepwise
analysis of interactions between fungal hyphae and PMN that ultimately
result in killing of the organisms. Initially, experiments will
concentrate on interactions os PMN with Candida albicans, with additional
studies using Aspergillus fumigatus and Rhizopus oryzae for specific
aspects likely to differ, if time permits. Opsonized and unopsonized
hyphae elicit different patterns of early PMN responses leading to
activation of the PMN respiratory burst that is required for hyphal
killing. Previous data provide initial clues to the identity of apparently
separate PMN binding and activation sites as well as interacting ligands on
opsonized and unopsonized hyphae. These will be further pursued using
specific MAbs combined with hyphae selectively opsonized with individual
serum factors reactive with PMN receptors. Activation of specific
receptors will be linked to initiation of early PMN ion fluxes and
biochemical events to determine events and pathways necessary and
sufficient for activation of the respiratory burst and degranulation.
Recent data imply that both are required for fungicidal effects.
Identification of pathways for initial PMN activation will continue,
including studies of temporal involvement of specific phospholipases,
phospholipids, and possible endogenous mediators derived from arachidonic
acid-containing or other lipids. Hyphal killing by PMN is a relatively
slow process, not attributable to the almost immediate lethal effects of
cell-free oxidants. To define the mechanisms and loci of lethal hyphal
damage by PMN, a combined approach will employ both intact PMN and
granule-depleted cytoplast with added granule constituents separately or in
combination (e.g., myeloperoxidase, defensins, cathepsin G, lactoferrin,
lysozyme and elastase). In addition to processes initiating PMN responses
to hyphae, we will begin to identify and study factors modulating the
sustained PMN activation response required for killing. To define effects
of PMN on the target organisms, temporal biochemical and visual changes in
multiple localized fluorescent markers loaded into live hyphae will be
correlated with localized biochemical indicators of damage, PMN oxidant and
granule release, and their coincidence with the onset of killing.
National Institute of Allergy and Infectious Diseases
CFDA Code
DUNS Number
005492160
UEI
JZ8RQC4EMDZ5
Project Start Date
01-September-1978
Project End Date
30-November-1995
Budget Start Date
01-December-1993
Budget End Date
30-November-1994
Project Funding Information for 1994
Total Funding
$360,625
Direct Costs
$211,279
Indirect Costs
$149,346
Year
Funding IC
FY Total Cost by IC
1994
National Institute of Allergy and Infectious Diseases
$360,625
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01AI015338-16
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01AI015338-16
Patents
No Patents information available for 5R01AI015338-16
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01AI015338-16
Clinical Studies
No Clinical Studies information available for 5R01AI015338-16
News and More
Related News Releases
No news release information available for 5R01AI015338-16
History
No Historical information available for 5R01AI015338-16
Similar Projects
No Similar Projects information available for 5R01AI015338-16